Deutsche Bank AG Buys New Position in Progyny, Inc. $PGNY

Deutsche Bank AG acquired a new stake in Progyny, Inc. (NASDAQ:PGNY) in the 2nd quarter, Holdings Channel.com reports. The institutional investor acquired 71,104 shares of the company’s stock, valued at approximately $2,050,000.

A number of other hedge funds also recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Progyny during the fourth quarter worth about $25,000. Hantz Financial Services Inc. boosted its holdings in Progyny by 79.4% in the fourth quarter. Hantz Financial Services Inc. now owns 1,676 shares of the company’s stock valued at $43,000 after purchasing an additional 742 shares during the last quarter. Canada Pension Plan Investment Board purchased a new position in Progyny in the second quarter valued at about $77,000. Quarry LP increased its holdings in Progyny by 2,004.1% during the 3rd quarter. Quarry LP now owns 3,598 shares of the company’s stock worth $77,000 after purchasing an additional 3,427 shares during the last quarter. Finally, New Age Alpha Advisors LLC purchased a new stake in Progyny during the 4th quarter worth approximately $94,000. Hedge funds and other institutional investors own 94.93% of the company’s stock.

Progyny Stock Up 0.5%

Progyny stock opened at $26.00 on Friday. Progyny, Inc. has a 52-week low of $16.10 and a 52-week high of $33.06. The firm has a market capitalization of $1.99 billion, a price-to-earnings ratio of 28.26, a PEG ratio of 1.78 and a beta of 1.01. The firm has a 50-day moving average price of $29.08 and a two-hundred day moving average price of $23.63.

Progyny (NASDAQ:PGNY) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.55 earnings per share for the quarter, beating analysts’ consensus estimates of $0.33 by $0.22. Progyny had a return on equity of 15.98% and a net margin of 6.00%.The company had revenue of $350.51 million for the quarter, compared to analysts’ expectations of $349.05 million. During the same quarter in the previous year, the company posted $0.19 earnings per share. The business’s revenue for the quarter was up 5.3% compared to the same quarter last year. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. Research analysts expect that Progyny, Inc. will post 1.25 earnings per share for the current year.

Progyny declared that its board has initiated a stock repurchase plan on Tuesday, May 26th that authorizes the company to repurchase $200.00 million in shares. This repurchase authorization authorizes the company to repurchase up to 10.3% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s board of directors believes its stock is undervalued.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Wells Fargo & Company began coverage on Progyny in a research note on Thursday, August 20th. They set an “overweight” rating and a $37.00 target price for the company. Leerink Partners set a $38.00 price objective on shares of Progyny in a research note on Wednesday, July 22nd. KeyCorp raised their price objective on shares of Progyny from $30.00 to $35.00 and gave the stock an “overweight” rating in a report on Monday, July 13th. Zacks Research raised shares of Progyny from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, July 8th. Finally, Citizens Jmp upped their target price on shares of Progyny from $30.00 to $31.00 and gave the company a “market outperform” rating in a research note on Monday, May 11th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $33.91.

Insiders Place Their Bets

In other news, CFO Mark S. Livingston sold 2,517 shares of the firm’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $25.50, for a total transaction of $64,183.50. Following the transaction, the chief financial officer directly owned 74,688 shares of the company’s stock, valued at approximately $1,904,544. This trade represents a 3.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Cheryl Scott sold 7,439 shares of Progyny stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $26.39, for a total transaction of $196,315.21. Following the sale, the director owned 19,772 shares in the company, valued at approximately $521,783.08. This represents a 27.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 13,563 shares of company stock worth $351,968. Insiders own 9.90% of the company’s stock.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.